Europe is entering a decisive moment for ATMP innovation. With the EU Biotech Act signalling a renewed push for health‑innovation sovereignty and the 2026 Horizon Europe Health Calls preparing major new funding opportunities — including support for clinical trials — the region has a narrow window to strengthen its competitiveness.

Yet clinical trial activity is declining, global competition is intensifying, and Europe’s ability to deploy its existing capacity is under real pressure.

Hosted by Phacilitate, this webinar brings together leading voices to explore:

Europe’s execution gap in the ATMP roadmap

What the Biotech Act means for innovation, manufacturing and sovereignty

How the next Horizon Europe calls could reshape clinical trial activity

The structural challenges preventing Europe from becoming a true hub for ATMP trials

What must change now for Europe to remain globally relevant

All key content pillars for our European meeting in Barcelona this September.

Montse Daban Marin, Director of Strategy and Global Partnerships, Biocat

Paolo Morgese, VP Public Affairs Europe, Alliance for Regenerative Medicine

Jacqueline Barry, Chiel Clinical Officer, Cell and Gene Therapy Catapult

Jim Lund, Chief Business Development Officer, CCRM Nordic

Join us on July 15, 2 pm as we set the stage for a critical conversation ahead of Advanced Therapies Europe: Can Europe turn policy ambition into execution — and secure its place in the global ATMP landscape?

Europe’s ATMP Roadmap: From Strategy to Execution in a New Global Reality